PSMD1 and COVID-19: The neutralizing VH114 nanobody should be tested and developed further for use as a safe, passive, immunotherapeutic agent against COVID-19—preferably in a neutralizing mAb cocktail, as one epitope-specific mAb should not be sufficiently effective to block completely the S1–hACE2 interaction.